Mr Joseph Norris

Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries - PubMed

Focal therapy using up to two sessions of focal HIFU or cryotherapy could be considered as a first-line treatment for well-selected patients of nonmetastatic prostate cancer alongside radical treatment. Future research priorities should include the development of a dedicated prognostic risk calculat …

#urology #prostatecancer #prostatehealth #menshealth #privatehealthcare #chelseaandwestminsterprivatecare | Private Care at Chelsea and Westminster Hospital

🌟 Welcome Mr Joseph Norris to Our Private Care Team 🌟 We are delighted to welcome Mr Joseph Norris, Consultant Urological Surgeon, to Chelsea and Westminster Private Care. Mr Norris specialises in prostate cancer and benign prostate conditions, with particular expertise in minimally invasive and focal therapies, including HIFU, NanoKnife, cryotherapy, GreenLight laser therapy, Rezūm and UroLift. Alongside his clinical practice, Mr Norris is an internationally recognised researcher with more than 180 peer-reviewed publications and holds leadership roles in urology education and service improvement at Chelsea and Westminster Hospital. We are delighted to welcome Mr Norris to our growing private care team and look forward to the expertise and innovation he brings to patient care. #Urology #ProstateCancer #ProstateHealth #MensHealth #PrivateHealthcare #ChelseaAndWestminsterPrivateCare

A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review

Objectives: To systematically review erectile function (EF) outcomes following primary whole gland (WG) and focal ablative therapies for localized prostate cancer to ascertain whether the treatment modality or intended treatment volume affects the time taken to recover baseline EF. Method and materials: A systematic review was performed according to the preferred reporting items for systematic review and meta-analysis statement. Inclusion criteria were men with localized prostate cancer treated with primary, ablative therapy. Primary outcome was the return to baseline EF measured with objective, validated symptoms scores. Secondary outcome was use of phosphodiesterase inhibitors or erectile aids. Meta-analysis was not performed owing to heterogenous outcome measures. Results: Of 222 articles identified in February 2017, 55 studies which reported EF after ablative therapy were identified but only 17 used validated outcome measures and met inclusion criteria. WG cryotherapy was used in 2 studies, WG high-intensity focused ultrasound (HIFU) in 5, focal cryotherapy in 2, focal HIFU in 3, focal phototherapy or laser therapy in 4, vascular-targeted photodynamic therapy in 3, and irreversible electroporation in 2. WG cryotherapy was associated with a significant decline in EF at 6 months with minimal improvement at 36 months. Baseline IIEF-15 of patients undergoing focal HIFU fell 30 points at 1 month but returned to baseline by 6 months. The remaining focal therapies demonstrated minimal or no effect on EF, but the men in these studies had small foci of disease. The review is limited by lack of randomized studies and heterogenous outcome measures. Conclusions: Most studies assessing the outcomes of focal therapy on sexual function were not of high quality, used heterogenous outcomes, and had relatively short follow up, highlighting the need for more robustly designed studies using validated patient reported outcome measures for comparison. However, FT in general resulted in less effect on EF than WG ablation. Keywords: Cryotherapy; Erectile dysfunction; Focal therapy; HIFU.